Bristol-Myers impresses with cancer drug combo ahead of ASCO
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb’s experimental immunotherapy combined with its approved cancer drug Yervoy worked to substantially shrink tumors in patients with advanced melanoma in an early-stage study.